Moderna: reduces losses, confident about long term

Published: 2025-05-02 08:40:19 ET MRNA

Published on 05/02/2025 at 08:40

Moderna reported total revenue of $108m for Q1 2025, down 35% from the same period a year earlier. The decline was primarily due to lower net sales of $86m over the quarter, reflecting lower vaccination rates compared to the same period last year.The laboratory reported operating expenses of $1.158bn, down 19%, including a 19% decline in R&D expenses, which fell from $1.063bn to $856m. The group ultimately posted a net loss of $971m, down 17% from the $1.175bn loss recorded a year earlier at the end of Q1. EPS came in at - $2.52, compared with -$3.07 a year earlier. "In the first quarter, we continued to execute with financial discipline, significantly reducing our operating expenses and further focusing our investments on oncology," it said. "Looking ahead, we are reiterating our financial guidance for 2025 and announcing a cost structure that is expected to reduce our annual operating expenses by approximately $1.5bn by 2027. With several Phase 3 trial results expected in the near term and sustained momentum toward approval of 10 products, we remain confident in Moderna's long-term outlook."Copyright (c) 2025 CercleFinance.com. All rights reserved.